Biological therapy for ulcerative colitis: An update

Inflammatory pathways of importance for management of inflammatory bowel disease

(2014) Jannie Pedersen   WORLD JOURNAL OF GASTROENTEROLOGY

Optimizing anti-TNF treatments in inflammatory bowel disease

(2013) Shomron Ben-Horin et al.   AUTOIMMUNITY REVIEWS

Vedolizumab for the Treatment of IBD: A Selective Therapeutic Approach Targeting Pathogenic a4b7 Cells

(2013) Manol Jovani et al.   CURRENT DRUG TARGETS

Treatment of ulcerative colitis

(2013) Wojciech Blonski et al.   CURRENT OPINION IN GASTROENTEROLOGY

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

(2013) Yasuo Suzuki et al.   JOURNAL OF GASTROENTEROLOGY

Antagonizing the  4 1 Integrin, but Not  4 7, Inhibits Leukocytic Infiltration of the Central Nervous System in Rhesus Monkey Experimental Autoimmune Encephalomyelitis

(2013) K. G. Haanstra et al.   JOURNAL OF IMMUNOLOGY

Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype

(2013) Catherine Milch et al.   JOURNAL OF NEUROIMMUNOLOGY

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year

(2012) F. Vincenti et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

(2012) Arthur Kavanaugh et al.   ARTHRITIS AND RHEUMATISM

Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates

(2012) Eric R. Fedyk et al.   INFLAMMATORY BOWEL DISEASES

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune aspects of the pathogenesis of inflammatory bowel disease

(2012) Tadakazu Hisamatsu et al.   PHARMACOLOGY & THERAPEUTICS

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study

(2011) Jürgen Braun et al.   ANNALS OF THE RHEUMATIC DISEASES

New therapies for inflammatory bowel disease: from the bench to the bedside

(2011) Silvio Danese   GUT

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

(2011) Kamran Ghoreschi et al.   JOURNAL OF IMMUNOLOGY

Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

(2010) Asher Kornbluth et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Tumor Necrosis Factor-α Monoclonal Antibodies in the Treatment of Inflammatory Bowel Disease: Clinical Practice Pharmacology

(2010) Thomas W. Lee et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Biologic Therapies Against Inflammatory Bowel Disease: A Dysregulated Immune System and the Cross Talk with Gastrointestinal Mucosa Hold the Key

(2010) Poonam Dharmani et al.   Current Molecular Pharmacology

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

(2009) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis

(2009) Mary G. Boy et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Selectivity and therapeutic inhibition of kinases: to be or not to be?

(2009) Kamran Ghoreschi et al.   NATURE IMMUNOLOGY

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

(2008) Jonathan Kay et al.   ARTHRITIS AND RHEUMATISM

Therapeutic targeting of Janus kinases

(2008) Marko Pesu et al.   IMMUNOLOGICAL REVIEWS